dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Barbui, Tiziano |
dc.contributor.author | De Stefano, Valerio |
dc.contributor.author | Alvarez-Larran, Alberto |
dc.contributor.author | Iurlo, Alessandra |
dc.contributor.author | Masciulli, Arianna |
dc.contributor.author | Carobbio, Alessandra |
dc.contributor.author | Fox, Maria Laura |
dc.date.accessioned | 2021-06-09T11:01:29Z |
dc.date.available | 2021-06-09T11:01:29Z |
dc.date.issued | 2021-02-04 |
dc.identifier.citation | Barbui T, De Stefano V, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, et al. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer J. 2021 Feb 4;11:21. |
dc.identifier.issn | 2044-5385 |
dc.identifier.uri | https://hdl.handle.net/11351/6042 |
dc.description | Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; nfectious diseases; Myeloproliferative disease; Risk factors |
dc.description.abstract | In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15 major thromboses (3 arterial and 12 venous) were registered in 14 patients, of whom all, but one, were receiving LMW-heparin prophylaxis. After adjustment for the competing risk of death, the cumulative incidence of arterial and venous thromboembolic events (VTE) reached 8.5% after 60 days follow-up. Of note, 8 of 12 VTE were seen in ET. Interestingly, at COVID-19 diagnosis, MPN patients had significantly lower platelet count (p < 0.0001) than in the pre-COVID last follow-up.This decline was remarkably higher in ET (−23.3%, p < 0.0001) than in PV (−16.4%, p = 0.1730) and was associated with higher mortality rate (p = 0.0010) for pneumonia. The effects of possible predictors of thrombosis, selected from those clinically relevant and statistically significant in univariate analysis, were examined in a multivariate model. Independent risk factors were transfer to ICU (SHR = 3.73, p = 0.029), neutrophil/lymphocyte ratio (SHR = 1.1, p = 0.001) and ET phenotype (SHR = 4.37, p = 0.006). The enhanced susceptibility to ET-associated VTE and the associated higher mortality for pneumonia may recognize a common biological plausibility and deserve to be delved to tailor new antithrombotic regimens including antiplatelet drugs. |
dc.language.iso | eng |
dc.publisher | Springer Nature |
dc.relation.ispartofseries | Blood Cancer Journal;11 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | COVID-19 (Malaltia) - Factors de risc |
dc.subject | Tromboembolisme |
dc.subject.mesh | Venous Thromboembolism |
dc.subject.mesh | Coronavirus Infections |
dc.subject.mesh | /complications |
dc.title | Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41408-021-00417-3 |
dc.subject.decs | tromboembolia venosa |
dc.subject.decs | infecciones por Coronavirus |
dc.subject.decs | /complicaciones |
dc.relation.publishversion | https://doi.org/10.1038/s41408-021-00417-3 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Barbui T, Masciulli A, Carobbio A] FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy. [De Stefano V] Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico “A. Gemelli” IRCCS, Rome, Italy. [Alvarez-Larran A] Hospital Clinic de Barcelona, Barcelona, Spain. [Iurlo A] Hematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy. [Fox ML] Servei d’Hematologia, Vall d’Hebron Institute of Oncology (VHIO), Barcelona Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 33563901 |
dc.identifier.wos | 000618326700001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |